AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE
|
|
- Ira Parsons
- 5 years ago
- Views:
Transcription
1 AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria from Adamas and Eli Lilly and receives research support from Eli Lilly. This presentation will contain off-label discussion of new clinical trials looking at use of amyloid therapies (monoclonal antibodies and BACE inhibitors). 1
2 Objectives: Distinguish between the stages of Alzheimer disease (AD) which precede dementia, i.e. preclinical/at risk/stage 1, subjective cognitive impairment or decline (SCI or SCD)/stage 2, and early mild cognitive impairment/prodromal AD/stage 3. Explain the temporal progression and risk factors for progression and treatments for each stage of AD which precedes dementia. Apply recent research findings to be able to identify patients in these stages of AD. Classification of Alzheimer disease and neurodegenerative dementias Global deterioration score Clinical Dementia Rating scale Functional Assessment Staging of Alzheimer s Disease MMSE, neuropsychology Amyloid, tau, neurodegeneration Clinical Function Cognitive Biomarkers 2
3 The Global Deterioration Scale for Assessment of Primary Degenerative Dementia Developed by Dr. Barry Reisberg Provides caregivers an overview of the stages of cognitive function Broken down into 7 different stages Stages 1-3 are the pre-dementia stages Stages 4-7 are the dementia stages Beginning in stage 5, an individual can no longer survive without assistance. Am J Psychiatry Volume 139, Issue 9, September 1982, pp Level 1 No cognitive decline (Preclinical, At risk) 2 Very mild cognitive decline (Subjective Cognitive Impairment or Decline) Clinical Characteristics No subjective complaints of memory deficit & none clinically. Subjective complaints of memory deficit: (a) forgetting where one has placed familiar objects; (b) forgetting names one formerly knew well. No objective evidence of memory deficit on clinical interview. No objective deficits in employment or social situations. Appropriate concern with respect to symptomatology. 3 Mild cognitive decline (Prodromal, Mild Cognitive Impairment) 4 Moderate cognitive decline (Mild Dementia) Earliest clear-cut deficits. Manifestations one or more areas: (a) patient may have gotten lost when traveling to an unfamiliar location; (b) coworkers become aware of patient's relatively poor performance; (c) word and name finding deficit becomes evident to intimates; (d) patient may read a passage or a book and retain relatively little material; (e) patient may demonstrate decreased facility in remembering names upon introduction to new people; (f) patient may have lost or misplaced an object of value; (g) concentration deficit may be evident on clinical testing. Objective evidence of memory deficit obtained only with an intensive interview. Decreased performance in demanding employment and social settings. Denial. 3
4 ATN C. Jack A/T/N Score Amyloid Tau Neurodegeneration A-/T-/N- None None None A+/T-/N- A+/T+/N- CSF or PET amyloid + CSF or PET amyloid + A+/T-/N+ CSF or PET amyloid + A+/T+/N+ CSF or PET amyloid + None CSF p-tau elevated or PET tau + None CSF p-tau elevated or PET tau + A-/T+/N- None CSF p-tau elevated or PET tau + None CSF t-tau elevated, Abnl FDG PET c/w AD, MRI atrophy c/w AD CSF t-tau/fdg PET/MRI atrophy CSF t-tau/fdg PET/MRI atrophy None A-/T-/N+ None None CSF t-tau/fdg PET/MRI atrophy A-/T+/N+ None CSF p-tau elevated or PET tau + CSF t-tau/fdg PET/MRI atrophy Neurology 2016; 87:
5 Preclinical AD-pathophysiological process or AD-P 10 year + period prior to onset of clinical manifestations of AD or ADclinical (AD-C) 30% of 65yo and older have amyloid accumulation 18,000+ Ft Worth 31,000+ Dallas 5
6 RECENT LITERATURE ON PRECLINICAL AD What comes first? De Leon MJ et al. PLoS One 2018 Current thinking: reductions in the CSF levels of Aβ 42, which are associated with brain amyloid deposition, precede elevations in CSF tau levels, a marker of neurodegeneration and lower CSF Aβ 42 levels predict cognitive decline Transgenic animal models show CSF Aβ 42 elevations occur prior to Aβ 42 reductions and brain deposition, a trend also seen in early onset AD Utilizing cross-sectional (n = 766) and longitudinal data (n = 651) from three normal elderly cohorts with similar clinical and CSF protocols, we tested and confirm two major hypotheses: 1) CSF Aβ 42 levels have a non-linear relationship with both age and CSF biomarkers for tau pathology. We observed during mid to late-adult life, a quadratic or U- function uniquely and significantly described the CSF Aβ42 relationships to age and to CSF tau levels. For CSF Aβ38 or Aβ40, only linear relationships were found with age and tau levels; and 2) the cross-sectional and longitudinal results confirm the hypothesis that elevated Aβ42 levels contribute to the prediction of future cognitive decline. These data suggest that tau pathology precedes Aβ 42 pathology CSF biomarker studies that rely on decreased CSF Aβ 42 levels to identify brain amyloid sequestration and mark the onset of preclinical AD will have missed an earlier stage of elevated Aβ 42 also accompanied by elevated tau levels 6
7 How to identify Preclinical AD neuropsychologically: Accelerated long-term forgetting Present in autosomal dominant Alzheimer s disease mutation carriers, who were on average 7 years from predicted symptom onset Learning and recall of a 15-item word list, a short story, and a complex visual figure from the Adult Memory and Information Processing Battery At the 7-day telephone call, participants' free recall of the test materials was reassessed. For the figure, they were asked to draw the figure on a blank piece of paper included in the envelope, and for the verbal tests recall was done orally. Forced-choice recognition memory was then assessed Might be a very early feature of Alzheimer s disease-related cognitive decline Subtle increased subjective cognitive concerns also appear to be a presymptomatic feature of autosomal dominant Alzheimer s disease, which could be underpinned by accelerated long-term forgetting. Amyloid imaging is costly and CSF is invasive: Other imaging identification Eur J Nucl Med Mol Imaging Feb 2 The use of cognition as the primary outcome of clinical trials in individuals with preclinical AD difficult slow rate of change high sample sizes and long follow-up times Combined Aβ and tau thresholds can predict imminent neurodegeneration as an alternative framework with a high statistical power for testing the effect of diseasemodifying therapies on [ 18 F]FDG uptake decline over a typical 2-year clinical trial period in individuals with preclinical AD. 7
8 JAGS 2018 The presence of an abnormally high level of Aβ42 was unrelated to screen-positive depression Age was the only independent predictor of screen positive depression with the risk increasing 1.06 times for every additional year of age Oncotarget 2017 Oct 31;8(62): J Affect Disord 2018 Preclinical AD Studies FINGER study A4 DIAN/API Colombian Kindred EARLY GENERATIONS US POINTER 8
9 A Multidomain Two-Year Randomized Controlled Trial to Prevent Cognitive Impairment- the FINGER study The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) Investigated the effects of a 2-year intervention targeting several lifestyle and vascular risk factors simultaneously 1) Dietary guidance: Finnish Nutrition Recommendations 2) Physical activity: the Dose Responses to Exercise Training (DR s EXTRA) protocol 3) Cognitive training and social activities: 10 group sessions lead by a psychologist (approximately minutes/session) plus computer program and group discussions on memory-related themes (age-related changes in cognition, memory strategies, and every-day memory training). 4) Intensive monitoring and management of metabolic and vascular risk factors: Meet study nurse Q3mo during the first year, then Q6mo during the second year for anthropometric measurements (weight, blood pressure, hip and waist) The control group received regular health advice participants aged years Results: We found a significant beneficial intervention effect on overall cognitive performance. The beneficial effect was seen on each cognitive domain: memory; executive function, and psychomotor speed. Improvement in the neuropsychological test battery total score after 24 months was 25% higher in the intervention group than in the control group We also noted a significant intervention effect for the secondary cognitive outcomes of executive functioning (p=0 039) and processing speed (p=0 029) Improvement in executive functioning was 83% higher, and in processing speed 150% higher, in the intervention group than in the control group. The intervention was not associated with significant change in the prespecified memory domain. Conclusions: This is the first large RCT showing that it is possible to prevent cognitive decline using a multidomain intervention among older at-risk individuals. These results highlight the value of the feasible and novel multidomain approach that is effective for several cognitive domains. 9
10 Passive Immunization Against Amyloid The Dominantly Inherited Alzheimer Network (DIAN) Observational Study Enables researchers around the world to monitor and identify changes in individuals who carry one of the gene mutations (Presenilin1, Presenilin2 or APP) known to cause dominantly inherited Alzheimer s disease (DIAD). There is currently no treatment that can prevent or delay the progression of AD, and no new treatments have been approved in over ten years. DIAN aims to define the natural history of AD and establish reliable biomarkers that track with disease. 10
11 BACE1 inhibitor drugs in clinical trials for AD β-site amyloid precursor protein cleaving enzyme 1 (BACE1) β-secretase enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide Drug target for reducing the levels of Aβ in the brain Generation Two therapies given separately, both targeting amyloid, one IM and the other PO In participants at risk for the onset of clinical symptoms of Alzheimer's disease Cognitively unimpaired individuals with two APOE4 genes and age 60 to 75 years Randomized, double-blind, placebo-controlled, twocohort, parallel group design in which participants receive one of the investigational treatments or their matching placebo for at least 60 months up to a maximum of 96 months An unbalanced randomization (active: placebo) of 5:3 ratio in Cohort I (430 CAD106 :260 Placebo) and 3:2 ratio in Cohort II (390 CNP520 : 260 Placebo) will be applied Required to undergo at least two PET scans during the course of the study. Additional PET scans, blood and CSF collection will be voluntary 11
12 The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) Intervention Methods will Include: Physical Exercise Nutritional Counseling & Modification Cognitive & Social Stimulation Improved Self-Management of Health Status 2-year clinical trial To test whether lifestyle intervention focused on combining physical activity, healthy nutrition, social and intellectual challenge and improved self-management of medical conditions can protect cognitive function in older adults who are at increased risk for cognitive decline SUBJECTIVE COGNITIVE DECLINE 12
13 SCD Preprodromal or pre-mci stage of AD Biomarker evidence for AD plus subtle cognitive decline, which does not reach the level of objective impairment required for the MCI diagnosis Research Diagnostic Criteria: Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Normal age-, gender-, and educationadjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Neuron 84, Nov 5, 2014 Stage 0 no biomarker abnormalities; not thought to be on the AD trajectory Stage 1 cerebral amyloidosis Stage 2 amyloidosis + markers of neurodegeneration Stage 3 amyloidosis + neurodegeneration + subtle cognitive and behavioral decline that is not yet sufficient to meet criteria for mild cognitive impairment or dementia due to AD. 13
14 What about tau? 133 subjects HBAS, CDR 0 SMC questions Subjective cognitive decline in clinically healthy older adults manifests in the context of increasing entorhinal cortical tauopathy SCD marking one of the earliest behavioral changes among increasing pathologic change in clinically healthy older adults Entorhinal tauopathy in the presence of minimal Aβ load is argued to be the earliest component of the AD pathologic continuum, and as such, endorsement of SCD symptoms may represent the earliest signs of preclinical AD in some cases Have you recently experienced any change in your ability to remember things? [CHANGE IN MEMORY] Do you have more trouble than usual remembering a short list of items, such as a shopping list? [SHORT LIST] Do you have trouble remembering things from one second to the next? [ONE SECOND TO THE NEXT] Do you have much more trouble than usual remembering recent events? [RECENT EVENTS] Do you have any difficulty in understanding or following spoken instructions? [UNDERSTANDING INSTRUCTIONS] Do you have more trouble than usual following a group conversation or plot in a TV program due to your memory? [FOLLOWING A CONVERSATION] Do you have trouble finding your way around familiar streets? [GETTING LOST] JAMA Neurol Dec 1;74(12): Is it just normal aging? About 20% of older adults have subjective memory complaints A recent meta-analysis has revealed that about 25% of cognitively healthy older adults who report SCD will develop MCI due to AD in the next 4 years. In addition, these individuals have two-fold risk of progression to dementia during a 5-year follow-up period. Do you have memory complaints Our results suggest that SMC should not merely be considered as a benign agerelated phenomenon as our meta-analysis demonstrates that those with SMC are at significantly increased risk of future cognitive decline 99 ADNI participants with SCD: Being female, ApoE4, h/o tobacco smoking assoc with amyloid + Acta Psychiatrica Scandinavica 2014 & Compr Psychiatry
15 Vitamin D and Subjective Memory Complaint in Community-Dwelling Older Adults Subjective memory complaints memory lapses, problems learning new information, problems finding words, problems calculating problems concentrating Participants with 25OHD 68nmol/L had less often problems learning new information (P=0.027) There were no between-group differences for the other memory complaints Curr Alzheimer Research 2018 MCI 15
16 The concepts of early MCI (EMCI) and late MCI (LMCI) made on the basis of modest or advanced impairment of delayed recall of logical memory The concept of EMCI will bridge the gap between normal elderly memory function approximately 1.0 SD below expected education adjusted norms LMCI subjects are more amnestic than EMCI subjects approximately 1.5 SD below expectation. EMCI developed dementia at a rate of 2.3% and LMCI participants went on to dementia at a rate of 17.5% per year Wu L et al. PLoS ONE 7(10):e47905 ADNI MCI 1. Subject must have a subjective memory concern as reported by subject, study partner, or clinician. 2. Abnormal memory function documented by scoring within the education adjusted ranges on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale Revised (the maximum score is 25): a for 16 or more years of education. b. 5 9 for 8 15 years of education. c. 3 6 for 0 7 years of education. 3. Mini-Mental State Exam score between 24 and 30 (inclusive) (Exceptions may be made for subjects with less than 8 years of education at the discretion of the project director). 4. Clinical Dementia Rating = 0.5; Memory Box score must be at least General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit. 16
17 EMCI can be differentiated from HC and LMCI Functional connectivity in the precuneus, bilateral medial frontal, parahippocampal, middle temporal, right superior temporal, and left angular gyri was decreased in EMCI subjects compared with CN subjects LMCI subjects exhibited decreased functional connectivity in the precuneus, bilateral medial frontal gyri, and left angular gyrus, as compared to EMCI EMCI have more hippocampal atrophy than HC, more amyloid deposition ad higher total tau levels in CSF Alz Dis Assoc Disord. 2016:30(4); & Front. Aging Neurosci., 01 April 2013 & Alz Dement Jul;11(7):734-9 Brief clinical index to predict whether older adults diagnosed with amnestic MCI will progress to probable AD within 3 years Low risk (<20%) 0-2 points Moderate risk (21-89%) 3-8 points High risk (>90%) 9-16 points Lee SJ et al. PLoS ONE
18 Amyloid plaque reduction with aducanumab & Aducanumab effect (change from baseline) on CDR-SB and MMSE J Sevigny et al. Nature 537, (2016) doi: /nature19323 dtcs Age Interventions: reasoning training following transcranial direct current stimulation (tdcs) for 20 minutes using 2mA or less targeting the inferior frontal gyrus reasoning training following sham transcranial direct current stimulation (tdcs) on frontal- lobe mediated cognitive measures of executive control TDCS is thought to produce cognitive effects by modulating membrane potentials and the synaptic strength between stimulated neurons 18
19 Nicotinic acetylcholine receptor loss in AD & nicotine can improve cognitive performance Subjects with MCI that convert to AD have loss of nicotinic receptors Non-smoking adults, ages 55+, who either notice changes in their memory or whose family members notice memory changes may be eligible to participate. The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI. Connors Continuous Performance Test showed significant improvement with improvements in attention, memory, psychomotor speed, & overall subjective cognitive function The purpose of the SNIFF study is to find out whether a type of insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer s disease (AD). We are looking for 250 adults age diagnosed with amnestic mild cognitive impairment (amci) or early AD improving central nervous insulin signaling via intranasal insulin or insulin sensitizers, which cross the blood-brain barrier, could represent an effective way to prevent or treat AD In AD, there is reduced brain insulin receptor sensitivity & insulin receptors are altered by amyloid oligomers Improved delayed memory, improved metabolic function in brain 19
20 The Alzheimer s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer s disease. ADNI researchers collect, validate and utilize data such as MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors for the disease. Data from the North American ADNI s study participants, including Alzheimer s disease patients, mild cognitive impairment subjects and elderly controls, are available. 1, total participants will be enrolled across 3 cohorts: cognitively normal (CN), mild cognitive impairment (MCI), and mild AD dementia. Approximately, will be Rollover participants from ADNI2, and will be newly enrolled (inclusive) years of age neuroimaging and lumbar punctures to be carried out Neuropsychological testing 20
Mild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationClaims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association
Claims & Underwriting Alzheimer s & Cognitive Impairment: You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association 1 OVERVIEW Impact
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationMASSACHUSETTS ALZHEIMER S DISEASE RESEARCH CENTER
MASSACHUSETTS ALZHEIMER S THE NEWSLETTER DISEASE RESEARCH OF THE CENTER Volume 1, Issue 4 Winter 2010 http://madrc.mgh.harvard.edu/ Mild Cognitive Impairment (MCI) A new look at early changes MASSACHUSETTS
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationA Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationEuropean Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationAnxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?
The 2016 Annual Public Educational Forum Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links? Mary Ganguli MD MPH Professor of Psychiatry, Neurology, and Epidemiology, University of
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationEvaluation and Treatment of Dementia
Evaluation and Treatment of Dementia Jeffrey M. Burns, MD Edward H. Hashinger Professor of Neurology Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science Unit Disclosures
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationADNI PET CORE. Vancouver BC April Susan Landau, Andy Horng, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price
ADNI PET CORE Vancouver BC April 2016 Susan Landau, Andy Horng, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price ADNI FDG scan counts Number of FDG scans N SMC EMCI LMCI AD
More informationType 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky
Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory
More informationADNI PET CORE. Boston April Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price
ADNI PET CORE Boston April 27 Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price ADNI Florbetapir scan counts Number of Florbetapir scans N SMC EMCI LMCI AD Total
More informationEthical Issues in Alzheimer s Disease Clinical Trials: Genetic and Biomarker Disclosure
Ethical Issues in Alzheimer s Disease Clinical Trials: Genetic and Biomarker Disclosure Joshua Grill Associate Professor of Psychiatry and Human Behavior Alzheimer s Disease Research Center Institute for
More informationOverview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?
Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric
More informationMild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD
AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationMichael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center
Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center Dementia an acquired syndrome consisting of a decline in memory and other cognitive functions Alzheimer s Disease Fronto temporal
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationWashington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease
Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationLatest Methods to Early Detection for Alzheimer's: Cognitive Assessments and Diagnostic Tools in Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/alzheimers-disease-towards-earlier-detection/latest-methods-earlydetection-alzheimers-cognitive-assessments-and-diagnostic-tools-practice/8321/
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationMild cognitive impairment A view on grey areas of a grey area diagnosis
Mild cognitive impairment A view on grey areas of a grey area diagnosis Dr Sergi Costafreda Senior Lecturer Division of Psychiatry, UCL Islington Memory Service, C&I NHS FT s.costafreda@ucl.ac.uk London
More information4/28/2017. Aging with Down Syndrome. Second Annual USC UCEDD Community Education Conference May 19, 2017
Aging with Down Syndrome Second Annual USC UCEDD Community Education Conference May 19, 2017 Linda D. Nelson, M.Ed., Ed.S., Ph.D., ABN Board Certified Clinical Neuropsychologist Professor, Emerita, of
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationPersonal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders
Personal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders Dr. David B. Hogan Brenda Strafford Foundation Chair in Geriatric Medicine University of Calgary None to declare
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationAlzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT
Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms State of the art lecture March 4-2012 Philippe H Robert, Philippe Nice - France Robert The diagnosis of AD Neuropsychiatric
More informationAD Prevention Trials: An Industry Perspective
AD Prevention Trials: An Industry Perspective Robert A. Lasser, MD, MBA Global Development Lead, Product Development Group Medical Director, Neurodegenerative Disorders F. Hoffmann - La Roche Ltd Regulatory
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationMild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
Journal of Internal Medicine 2004; 256: 240 246 KEY SYMPOSIUM Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
More informationResearch ALZHEIMER S DISEASE AND RISK FACTORS
Research ALZHEIMER S DISEASE AND RISK FACTORS What is Alzheimer s disease? Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible disease of the
More informationDiagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16
The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei
More informationBrain Health and Risk Factors for Dementia
Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00
More informationPocket Reference to Alzheimer s Disease Management
Pocket Reference to Alzheimer s Disease Management Pocket Reference to Alzheimer s Disease Management Anna Burke, MD Geriatric Psychiatrist, Dementia Specialist Geri R Hall, PhD, ARNP, GCNS, FAAN Advanced
More informationKA Toulis, K. Dovas, M. Tsolaki. The endocrine facets of Alzheimer s disease and dementia-related disorders
KA Toulis, K. Dovas, M. Tsolaki The endocrine facets of Alzheimer s disease and dementia-related disorders Sex hormones Calcium metabolism GH/IGF-I Thyroid axis Metabolic hormones + dementia Sex hormones
More informationThe Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease
The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease AIBL: Two site collaborative study Study is conducted at two sites: Perth
More informationOutline. Minority Issues in Aging Research. The Role of Research in the Clinical Setting. Why Participate in Research
Outline Minority Issues in Aging Research Mary Sano, Ph.D Mount Sinai School of Medicine Bronx Veterans Medical Research Center 130 West Kingsbridge Rd Bronx NY, 10468 Phone: 718 741-4228; Fax: 718 562-9120
More informationThe Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD
The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD Division of Cognitive and Behavioral Neurology, Brigham and Women s Hospital Co-Director of the Center
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2012 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader October 2011 The Australian Imaging Biomarkers
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationDementia is not normal aging!
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
More informationEngineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
More informationAAIC 2018, Chicago, Illinois, US. July 22, 2018
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
More informationSHARED CARE OF MCI/EARLY DEMENTIA
SHARED CARE OF MCI/EARLY DEMENTIA BY DR. OLUFEMI BANJO MD, DTM, DCP, DIPA&DS, DHM, M.Med.Sc, FRCP(C) GERIATRIC PSYCHIATRIST. ASSISTANT MEDICAL DIRECTOR, ADULT MENTAL HEALTH AND ADDICTION, GRAND RIVER HOSPITAL
More informationResponse Ratio Female % Male % No Response(s) 1 <1 % Totals %
Constant Contact Survey Results Survey Name: Survey Questions for Researchers Status: Completed Filter: None Dec 03, 2008 1:30:39 PM What is your gender? Female 87 35.3 % Male 158 64.2 % No 1
More informationAPPENDIX SUPPLEMENTARY METHODS Control group criteria for each center... 2 strem2 ELISA protocol... 3 APPENDIX TABLES... 4
APPENDIX Content APPENDIX SUPPLEMENTARY METHODS... 2 Control group criteria for each center... 2 strem2 ELISA protocol... 3 APPENDIX TABLES... 4 Appendix Table S1. CSF core biomarkers cut-offs for each
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationINI. Therapeutic Effects of Intranasally-Administered Insulin (INI) for amci or Mild AD. Study of Nasal Insulin to Fight Forgetfulness (AKA)
INI Training Meeting Nov 5 th 2013, San Diego INI Therapeutic Effects of Intranasally-Administered Insulin (INI) for amci or Mild AD (AKA) Study of Nasal Insulin to Fight Forgetfulness Project Director
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationAdvances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017
Advances in Alzheimer s diagnosis; implications for clinical practice Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Grand Challenge Alzheimer s disease 47 million worldwide
More informationLambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School
Lambros Messinis PhD Neuropsychology Section, Department of Neurology, University of Patras Medical School Type 2 Diabetes Mellitus is a modern day epidemic Age is a significant predictor of diabetes Males
More informationAfter the Diagnosis: Rehabilitation & Support Options for Mild Dementia
After the Diagnosis: Rehabilitation & Support Options for Mild Dementia Dr. Toni Nicholls, Clinical Neuropsychologist Peronne Village, cottage #20, Worthing, Christ Church 621-2022 Say these aloud Dog
More informationEXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
More informationThe role of memory on patients with mild cognitive impairment. Sophia Vardaki, PhD National Technical University of Athens
The role of memory on patients with mild cognitive impairment Sophia Vardaki, PhD National Technical University of Athens Athens, 26 June 2015 Objective-Presentation Structure Objective To explore the
More informationClinical Study Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer s and Cognitively Normal Elderly
Hindawi Publishing Corporation Depression Research and Treatment Volume 2011, Article ID 396958, 6 pages doi:10.1155/2011/396958 Clinical Study Depressive Symptom Clusters and Neuropsychological Performance
More informationRisk Factors Associated with Cognitive Aging. Andrea Z. LaCroix, PhD. for the IOM Committee on the Public Health Dimensions of Cognitive Aging
Risk Factors Associated with Cognitive Aging Andrea Z. LaCroix, PhD. for the IOM Committee on the Public Health Dimensions of Cognitive Aging Lifestyle and Physical Environment Risk & Protective Factors
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationIndiana University School of Medicine, Indianapolis, IN USA 1
GWAS and Candidate Studies of MRI and Amyloid PET Phenotypes for Alzheimer's Disease Andrew J. Saykin Depts. of Radiology & Imaging Sciences and Medical & Molecular Genetics, Neurology & Psychiatry; Indiana
More informationMALATTIA CARDIOVASCOLARE NELL ANZIANO DIABETICO. Diabete e demenza. Enzo Manzato
MALATTIA CARDIOVASCOLARE NELL ANZIANO DIABETICO Diabete e demenza Enzo Manzato Lancet 2016; 387: 1513 Lancet 2016; 387: 1377 MEN Diabetes Care 2016;39:300 WOMEN Diabetes Care 2016;39:300 Multiple-adjusted
More information